Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02213926 · ClinicalTrials.gov registry record · Phase 2
An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma
A Phase 2 study of Mantle Cell Lymphoma (MCL), sponsored by Acerta Pharma.
- Active
- Registry status
- Phase 2
- Development phase
- 124
- Enrollment target
- 20
- Study locations
NCT02213926: Active Phase 2 study of Mantle Cell Lymphoma (MCL), sponsored by Acerta Pharma.
NCT02213926 is a Phase 2 study of Mantle Cell Lymphoma (MCL) that is active but no longer recruiting, run by Acerta Pharma. The registered enrollment target is 124 participants, below the 195-participant average among 9 other Mantle Cell Lymphoma (MCL) trials with a reported enrollment target (36% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02213926, a Phase 2 study of Mantle Cell Lymphoma (MCL), is active but no longer recruiting, sponsored by Acerta Pharma.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 124 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).
Primary Outcome
The overall response rate (ORR) is defined as the proportion of subjects achieving either a partial remission (response) (PR) or complete response (CR) according to the Lugano Classification for NHL (Cheson 2014) as assessed by investigators, where SD stands for Stable Disease, PD for Progressive Disease and NE for Not Evaluable.
Conditions Studied
Interventions
- DRUG ACP-196 (acalabrutinib)
Study Locations (20)
Other
- Research Site - Monash
- Research Site - Sydney
- Research Site - Wodonga
- Research Site - Bruges
- Research Site - Brussels
- Research Site - Brussels
- Research Site - Liège
- Research Site - Yvoir
- Research Site - Prague
- Research Site - Angers
- Research Site - Caen
Illinois
- Research Site - Chicago
- Research Site - Niles
- Research Site - Peoria
Florida
- Research Site - Tampa
Massachusetts
- Research Site - Boston
New Jersey
- Research Site - Hackensack
New York
- Research Site - New York
Texas
- Research Site - Houston
Washington
- Research Site - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2015-03-02 |
| Est. Completion | 2026-09-09 |
| Phase | Phase 2 |
What the registry record for NCT02213926 still lists
NCT02213926 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 195-participant average among 9 other Mantle Cell Lymphoma (MCL) trials with a reported enrollment target (36% lower).
The record links to 1 condition, with Mantle Cell Lymphoma (MCL) appearing as the primary indexed condition, and to 1 intervention - of which ACP-196 (acalabrutinib) is the first listed.
NCT02213926 names 20 study sites across 8 states, led by Other, Illinois, Florida.
Frequently Asked Questions
What is clinical trial NCT02213926 about?
NCT02213926 is a clinical study titled "An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma". The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).
What is the current status of trial NCT02213926?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 124 participants. The study started on 2015-03-02. Estimated completion is 2026-09-09.
What conditions does trial NCT02213926 study?
This clinical trial studies the following conditions: Mantle Cell Lymphoma (MCL).
What interventions are being tested in trial NCT02213926?
The interventions under investigation include: ACP-196 (acalabrutinib) (DRUG).
Who is sponsoring clinical trial NCT02213926?
This trial is sponsored by Acerta Pharma, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02213926 being conducted?
This trial has 20 study locations across Florida, Illinois, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mantle Cell Lymphoma (MCL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02213926's enrollment target sits among peer trials
124 5th of 9 higher than 5 of 9 other Mantle Cell Lymphoma (MCL) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mantle Cell Lymphoma (MCL) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
DALY II USA/ MB-CART2019.1 for DLBCL
RECRUITING · Phase 2
-
A Study of Acalabrutinib Plus Venetoclax and Rituximab in Participants With Treatment Naïve Mantle Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients
RECRUITING · Phase 1
-
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523014 · 124 participants · Phase 2
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
- NCT02670707 · 124 participants · Phase 3
Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
- NCT02830724 · 124 participants · Phase 1
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers
- NCT04748809 · 124 participants · NA
Effect of Anti-inflammatory Diet in Rheumatoid Arthritis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI